The Board remands the Veteran's claim for a compensable rating for residuals of prostate cancer, status post RALP, to obtain an adequate medical examination.
The deciding factor: The May 2024 VA examiner's report was deemed inadequate as it did not address voiding dysfunction and relied on insufficient evidence.
- Claimed conditions
- Residuals of prostate cancer, status post Robotic Assisted Laparoscopic Prostatectomy (RALP)
- How they argued it
- Direct service connection
- Exposure basis
- None
- Rating assigned
- None in this decision
- Decision date
- May 21, 2025
- Citation
- A25045733
What this means for you
A remand is not a loss. The Board sent the case back for more development — often a new exam or missing records — before making a final decision. Many remands later end in a grant, and the decision spells out exactly what the Board wanted to see.
What you can do next
Related decisions
Other Board decisions on a similar condition or argued the same way.
- Remanded (sent back)
The Board remands the claims for a rating reduction and increased rating for prostate cancer, as well as the TDIU claim, due to the need for additional development of evidence.
- Denied
The Board denied an earlier effective date for service connection of residuals of prostate cancer, finding that the August 10, 2022 effective date is appropriate under the PACT Act.
- Denied
The Board denied the appeals for increased ratings and TDIU, as the evidence did not support higher ratings or unemployability due to service-connected disabilities.
- Granted
The Veteran was granted special monthly compensation (SMC) based on the need for aid and attendance due to a service-connected prostate disability.
We are not the VA. Veterans’ Rights is an independent resource built for veterans. We are not the U.S. Department of Veterans Affairs, not part of the government, and not endorsed by any government agency.
This is general information, not legal advice. For advice about your own situation, talk to a VA-accredited representative — many help for free.